Manufacturers should not wait for final HTA scopes to test whether their evidence package can addres...
Read moreThe first EU Joint Clinical Assessments (JCAs) are now providing real-world evidence of how the new ...
Read moreThe publication of the first three EU Joint Clinical Assessments (JCAs) provides the first opportuni...
Read moreIntroduction An EU-focused PICOS (population, intervention, comparator, outcomes or study-type) fram...
Read moreExecutive Summary Rare disease assessments rely on specialist clinical and patient expertise to inte...
Read moreAs NICE and EU Joint Clinical Assessment (JCA) requirements increasingly need to be considered in pa...
Read morePricing strategy is often treated as a launch activity. However, by the time teams begin detailed pr...
Read moreThe first EU Joint Clinical Assessment (JCA) has now been published, providing the first practical i...
Read moreExpert contributions are critical to health technology assessment (HTA), particularly in rare diseas...
Read moreSpain has published Royal Decree 415/2026[1], setting out a new national framework for health techno...
Read more